|
|
|
|
Scientific Advisory Board
Ernst J. Schaefer, MD
Chief Medical Officer
Dr. Schaefer is Co-Founder and Chief Medical Officer of Boston Heart Lab. He and Dr. Asztalos (see below) have developed our company’s proprietary technology to measure HDL particles and developed the revolutionary new method to use HDL particle concentrations as a much more effective predictor for cardiovascular disease (CVD).
Dr. Schaefer is a distinguished professor at the Tufts University School of Medicine and the Friedman School of Nutrition Science and Policy at Tufts University.
He received the J.D. Lane Award of the U.S. Public Health Service (1981) and the Irvine H. Page Arteriosclerosis Research Award from the American Heart Association (1981) for defining the metabolic defect in Tangier disease and describing two new genetic disorders apoA-I/C-III/A-IV and apoE deficiency characterized by severe lipoprotein abnormalities and premature heart disease. Further did Dr. Schaefer received the Saul Horowitz Research Award from Mt. Sinai School of Medicine (1989), Oliver Smith Awards of Tufts-New England Medical Center for Patient Care (1999, 2001, 2003), the E.V. McCollum Research Award of the American Society for Clinical Nutrition (2000), and a Distinguished Faculty Award from Tufts University (2001). Since 1997 he has been a member of Who’s Who in America, and in 2004 was named among America’s Top Physicians by the Consumers Research Council of America.
Dr. Schaefer is an author or co-author of over 400 publications and served on the first and second adult treatment panels of the National Cholesterol Education Program of the National Institutes of Health, on the Nutrition Study Section and as chairman of the Metabolism Study Section of the NIH, and the Nutrition Committee of the American Heart Association. Since 1997 Dr. Schaefer has been the U.S. editor of the journal Atherosclerosis, the official journal of the European Atherosclerosis Society, and also serves on the Clinical Research Review Committee and Study Section of the NIH.
Bela F. Asztalos, Ph.D
Chief Scientific Officer
Dr. Asztalos is the Chief Scientific Officer of Boston Heart Lab and an inventor of the two-dimensional gel electrophoresis lipoprotein technology. He serves as a scientist of the Lipid Metabolism Laboratory of the Jean Mayer USDA HNRCA at Tufts University and has authored numerous publications related to his research on HDL cholesterol structure and function. Dr. Asztalos received his Ph.D. in Biochemistry from the Attila Jozsef University in Szeged, Hungary.
Katsuyuki Nakajima, Ph.D
Director, Research and Development
Dr. Nakajima received his B.A from Hokkaido University, his B.M.S from the Metabolism Division of Institute for Protein Research, Osaka University. From 1968 to 1972, he worked at the Gunma Institute for Public Health (Clinical Pathology Division) (Maebashi, Gunma) on Itai-Itai disease (heavy metal pollution) and volcanic gas toxicity. He received Ph. D in 1975 from Department of Human Nutrition, Osaka University School of Medicine. Since 1978, he has been a member of Otsuka Pharmaceutical, Co., Ltd. and affiliated companies. He was the Managing Director of Otsuka Assay Laboratories (Tokushima) until 1987 and the Managing Director of diagnostic division at Japan Immuroresearch Laboratories, Co., Ltd (Takasaki) (a subsidiary of Otsuka Pharmaceutical, Co Ltd).
From 1995 to 2000, Dr. Nakajima worked at Otsuka America Pharmaceutical, Inc in Rockville, MD. While at Otsuka America, he obtained FDA approval of remnant lipoprotein cholesterol (RLP-C) assay kit for the diagnosis of heart disease risk. He has received an award for the development of new clinical chemistry technology from Japanese Association of Clinical Chemistry in 2001, Outstanding Research Award from Tufts University (Boston) in 2002 and an Award for Contribution to Laboratory Science from American Association of Clinical Chemistry (Philadelphia) in 2003. He is an author or co-author of over 150 publications written in both in English and in Japanese. His research focuses on diagnostics of plasma lipoproteins and lipid disorders.
|
|
|
|
|
 |
 |
|
 |
 |
|
